Search Results for: CDK6

148 interactions involving CDK6 - cyclin dependent kinase 6 found:

Sort by: Symbol Number of Pathways Number of Drugs Number of Diseases
Novel Symbol Description Pathways Hide Drugs Hide Diseases Hide
Novel ACHE acetylcholinesterase (Yt blood group)
  • Neurotransmitter clearance
  • Synthesis of PC
  • Synthesis, secretion, and deacylation of Ghrelin
  • Choline
  • Tacrine
  • Dipivefrin
  • Gallamine triethiodide
  • Pyridostigmine
  • Galantamine
  • Isoflurophate
  • Pralidoxime
  • Minaprine
  • Donepezil
  • Ranitidine
  • Ethanol
  • Demecarium
  • Physostigmine
  • Rivastigmine
  • Edrophonium
  • Ambenonium
  • Tubocurarine
  • Decamethonium
  • Neostigmine
  • Monoisopropylphosphorylserine
  • Propidium
  • 3,8-Diamino-6-Phenyl-5-[6-[1-[2-[(1,2,3,4-Tetrahydro-9-Acridinyl)Amino]Ethyl]-1h-1,2,3-Triazol-4-Yl]Hexyl]-Phenanthridinium
  • 3,6,9,12,15-Pentaoxaheptadecane
  • 1-Deoxy-1-Thio-Heptaethylene Glycol
  • (4aS,6R,8aS)-11-[8-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)octyl]-6-hydroxy-3-methoxy-5,6,9,10-tetrahydro-4aH-[1]benzofuro[3a,3,2-ef][2]benzazepin-11-ium
  • Methylphosphinate
  • Methylphosphinic Acid
  • 3,8-Diamino-6-Phenyl-5-[6-[1-[2-[(1,2,3,4-Tetrahydro-9-Acridinyl)Amino]Ethyl]-1h-1,2,3-Triazol-5-Yl]Hexyl]-Phenanthridinium
  • beta-L-fucose
  • Huperzine B
  • M-(N,N,N-Trimethylammonio)-2,2,2-Trifluoro-1,1-Dihydroxyethylbenzene
  • N-acetyl-alpha-D-glucosamine
  • 2-(N-morpholino)ethanesulfonic acid
  • MF268
  • 3-Chloro-9-Ethyl-6,7,8,9,10,11-Hexahydro-7,11-Methanocycloocta[B]Quinolin-12-Amine
  • NAP-226-90
  • (R)-tacrine(10)-hupyridone
  • (S)-tacrine(10)-hupyridone
  • TACRINE(8)-4-AMINOQUINOLINE
  • (9S)-9-[(8-AMMONIOOCTYL)AMINO]-1,2,3,4,9,10-HEXAHYDROACRIDINIUM
  • Zanapezil
  • Huperzine A
  • Phenserine
  • Itopride
  • Ganstigmine
  • Hydroxy(oxo)(2-{(1S)-2,2,2-trifluoro-1-[2-(trimethylarsonio)ethoxy]ethyl}phenyl)ammonium
  • 1-BENZYL-4-[(5,6-DIMETHOXY-1-INDANON-2-YL)METHYL]PIPERIDINE
  • 1-[3-({[(4-AMINO-5-FLUORO-2-METHYLQUINOLIN-3-YL)METHYL]THIO}METHYL)PHENYL]-2,2,2-TRIFLUOROETHANE-1,1-DIOL
  • (3,4,8b-Trimethyl-3-oxido-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-3-ium-7-yl) N-(2-ethylphenyl)carbamate
  • Methylthioninium
  • Diethylene glycol diethyl ether
  • 2-[4-(DIMETHYLAMINO)PHENYL]-6-HYDROXY-3-METHYL-1,3-BENZOTHIAZOL-3-IUM
  • Dimetacrine
  • Terpinen-4-ol
  • Tyrothricin
  • Choline salicylate
Novel ARHGEF6 Rac/Cdc42 guanine nucleotide exchange factor 6
  • NRAGE signals death through JNK
  • G alpha (12/13) signalling events
  • Regulation of cytoskeletal remodeling and cell spreading by IPP complex components
  • G beta:gamma signalling through CDC42
  • CDC42 GTPase cycle
  • RAC1 GTPase cycle
  • RHOU GTPase cycle
  • Non-syndromic X-linked mental retardation
Novel CDK14 cyclin dependent kinase 14
Novel CTNNA1 catenin alpha 1
  • Adherens junctions interactions
  • VEGFR2 mediated vascular permeability
  • Myogenesis
  • Myogenesis
  • RHO GTPases activate IQGAPs
  • Regulation of CDH11 function
  • Regulation of CDH19 Expression and Function
  • Regulation of CDH1 Function
  • Degradation of CDH1
  • CDH11 homotypic and heterotypic interactions
Novel GOLGA4 golgin A4
  • Retrograde transport at the Trans-Golgi-Network
  • Signaling by membrane-tethered fusions of PDGFRA or PDGFRB
Novel HPD 4-hydroxyphenylpyruvate dioxygenase
  • Tyrosine catabolism
  • Nitisinone
  • DAS869
  • Tyrosinemia; Tyrosinemia, type I; Tyrosinemia, type II; Tyrosinemia, type III; Hawkinsinuria
Novel KRIT1 KRIT1 ankyrin repeat containing
  • Cerebral cavernous malformation
Novel RGS3 regulator of G protein signaling 3
  • G alpha (q) signalling events
  • G alpha (i) signalling events
Novel SGCE sarcoglycan epsilon
  • Formation of the dystrophin-glycoprotein complex (DGC)
  • Formation of the dystrophin-glycoprotein complex (DGC)
  • Primary torsion dystonia (PTD)
Novel TAC1 tachykinin precursor 1
  • Tachykinin receptors bind tachykinins
  • G alpha (q) signalling events
Novel TAL2 TAL bHLH transcription factor 2
ABI2 abl interactor 2
  • Regulation of actin dynamics for phagocytic cup formation
  • Regulation of actin dynamics for phagocytic cup formation
  • VEGFA-VEGFR2 Pathway
  • RHO GTPases Activate WASPs and WAVEs
  • RHO GTPases Activate WASPs and WAVEs
  • RAC1 GTPase cycle
  • RAC2 GTPase cycle
  • RAC3 GTPase cycle
  • FCGR3A-mediated phagocytosis
  • FCGR3A-mediated phagocytosis
AKT1 AKT serine/threonine kinase 1
  • Activation of BAD and translocation to mitochondria
  • PIP3 activates AKT signaling
  • PIP3 activates AKT signaling
  • Downregulation of ERBB2:ERBB3 signaling
  • Translocation of SLC2A4 (GLUT4) to the plasma membrane
  • Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
  • MTOR signalling
  • AKT phosphorylates targets in the cytosol
  • AKT phosphorylates targets in the cytosol
  • AKT phosphorylates targets in the nucleus
  • Negative regulation of the PI3K/AKT network
  • eNOS activation
  • AKT-mediated inactivation of FOXO1A
  • Integrin signaling
  • Deactivation of the beta-catenin transactivating complex
  • CD28 dependent PI3K/Akt signaling
  • Co-inhibition by CTLA4
  • G beta:gamma signalling through PI3Kgamma
  • Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA
  • KSRP (KHSRP) binds and destabilizes mRNA
  • VEGFR2 mediated vascular permeability
  • TP53 Regulates Metabolic Genes
  • Constitutive Signaling by AKT1 E17K in Cancer
  • Interleukin-4 and Interleukin-13 signaling
  • Regulation of TP53 Degradation
  • Regulation of TP53 Activity through Acetylation
  • Regulation of TP53 Activity through Association with Co-factors
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Cyclin E associated events during G1/S transition
  • Cyclin A:Cdk2-associated events at S phase entry
  • PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1
  • RAB GEFs exchange GTP for GDP on RABs
  • RUNX2 regulates genes involved in cell migration
  • Regulation of PTEN stability and activity
  • Extra-nuclear estrogen signaling
  • Negative regulation of NOTCH4 signaling
  • FLT3 Signaling
  • Regulation of localization of FOXO transcription factors
  • Estrogen-dependent nuclear events downstream of ESR-membrane signaling
  • KEAP1-NFE2L2 pathway
  • SARS-CoV-2 targets host intracellular signalling and regulatory pathways
  • Mitochondrial unfolded protein response (UPRmt)
  • High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells
  • High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells
  • Mechanical load activates signaling by PIEZO1 and integrins in osteocytes
  • ATP
  • Arsenic trioxide
  • Genistein
  • Inositol 1,3,4,5-Tetrakisphosphate
  • Resveratrol
  • Archexin
  • Enzastaurin
  • Perifosine
  • N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
  • 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
  • PTEN hamartoma tumor syndrome (PHTS), including: Cowden syndrome; Bannayan-Riley-Ruvalcaba syndrome; Proteus syndrome; Proteus-like syndrome
ANKRD12 ankyrin repeat domain 12
APOBEC1 apolipoprotein B mRNA editing enzyme catalytic subunit 1
  • mRNA Editing: C to U Conversion
  • Formation of the Editosome
  • Zinc chloride
  • Zinc sulfate, unspecified form
AR androgen receptor
  • HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand
  • Nuclear Receptor transcription pathway
  • SUMOylation of intracellular receptors
  • Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3
  • Ub-specific processing proteases
  • RUNX2 regulates osteoblast differentiation
  • RUNX2 regulates osteoblast differentiation
  • Diethylstilbestrol
  • Levonorgestrel
  • Progesterone
  • Spironolactone
  • Flutamide
  • Oxandrolone
  • Fluphenazine
  • Testosterone
  • Mitotane
  • Estrone
  • Nilutamide
  • Tamoxifen
  • Norethisterone
  • Drostanolone
  • Norgestimate
  • Nandrolone phenpropionate
  • Ketoconazole
  • Acetophenazine
  • Bicalutamide
  • Fluoxymesterone
  • Drospirenone
  • Danazol
  • Testosterone propionate
  • Oxybenzone
  • 1-Testosterone
  • Boldenone
  • Calusterone
  • Periciazine
  • Prasterone
  • Flufenamic acid
  • Stanolone
  • (R)-Bicalutamide
  • Metribolone
  • (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE
  • Cyproterone acetate
  • LGD2941
  • Dimethylcurcumin
  • Oxymetholone
  • Methyltestosterone
  • Norelgestromin
  • Stanozolol
  • Tetrahydrogestrinone
  • (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
  • BMS-564929
  • S-23
  • 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
  • (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide
  • Andarine
  • (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
  • (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE
  • S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
  • 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
  • 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE
  • 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile
  • LGD-2226
  • 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
  • Triclosan
  • Nandrolone decanoate
  • Ulipristal
  • Enzalutamide
  • Eugenol
  • Dienogest
  • Norethynodrel
  • Norgestrel
  • Homosalate
  • Enzacamene
  • Luprostiol
  • Mibolerone
  • Phenothiazine
  • Gestrinone
  • Apalutamide
  • Clascoterone
  • Darolutamide
  • Esculin
  • Ligandrol
  • Testosterone cypionate
  • Testosterone enanthate
  • Testosterone undecanoate
  • Stanolone acetate
  • Segesterone acetate
  • Boldenone undecylenate
  • Echinacoside
  • Ketodarolutamide
  • Spinal and bulbar muscular atrophy (SBMA); Kennedy's disease
  • 46,XY disorders of sex development (Other), including: Persistent Mullerian duct syndrome; Hypospadias; Cryptorchidism
  • Prostate cancer
  • 46,XY disorders of sex development (Disorders in androgen synthesis or action), including: Congenital adrenal hyperplasias; Leydig cell hypoplasia; Androgen insensitivity syndrome (AIS)
ARAF A-Raf proto-oncogene, serine/threonine kinase
  • RAF activation
  • MAP2K and MAPK activation
  • Negative regulation of MAPK pathway
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF1 fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • SHOC2 M1731 mutant abolishes MRAS complex function
  • Gain-of-function MRAS complexes activate RAF signaling
  • ATP
  • Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
ARNT aryl hydrocarbon receptor nuclear translocator
  • Regulation of gene expression by Hypoxia-inducible Factor
  • PPARA activates gene expression
  • Phase I - Functionalization of compounds
  • Endogenous sterols
  • Xenobiotics
  • Aryl hydrocarbon receptor signalling
  • NPAS4 regulates expression of target genes
  • NPAS4 regulates expression of target genes
ATF6B activating transcription factor 6 beta
  • ATF6B (ATF6-beta) activates chaperones
  • ATF6B (ATF6-beta) activates chaperones
ATXN1 ataxin 1
  • Spinocerebellar ataxia (SCA); Machado-Joseph disease (SCA3)

Page 1 out of 8 pages